Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 15/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.32 |
| ▸ | ILK | Q13418 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | TTPA | P49638 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15821982 | 0.92 | LMNA (0.48) | LMNAMAPTMEN1GSTP1TTPA | |
| SCHEMBL15822118 | 0.92 | LMNA (0.48) | LMNAMAPTMEN1GSTP1TTPA | |
| SCHEMBL11399707 | 0.92 | LMNA (0.48) | LMNAMAPTMEN1GSTP1TTPA | |
| SCHEMBL15822117 | 0.92 | LMNA (0.48) | LMNAMAPTMEN1GSTP1TTPA | |
| SCHEMBL15821979 | 0.92 | LMNA (0.48) | LMNAMAPTMEN1GSTP1TTPA | |
| SCHEMBL215748 | 0.91 | AKT1 (0.31) | LMNAAKT1PDPK1PHLPP1ILK | |
| SCHEMBL17269266 | 0.91 | LMNA (0.36) | LMNA | |
| SCHEMBL17269118 | 0.91 | LMNA (0.36) | LMNA | |
| SCHEMBL12126630 | 0.86 | — | — | |
| SCHEMBL27845118 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| EP-2118249-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | Givaudan Nederland Services B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092678-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | LMNA 2425/4885AKT1 2988/4885PDPK1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.